Clareo Health | A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participants must be females of post-menopausal status with HR+, HER2- breast cancer that has spread to internal organs
Participants must have had at least one endocrine therapy
Participants must be willing to use a device to answer daily questions about how they are doing for the duration of their participation in the study
If participant has diarrhea from a previous treatment, they should talk to their doctor to ensure they have recovered enough to participate in this study
You may not be if
Participants must not have breast cancer that has spread to the brain if untreated and with symptoms
Participants must not have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy
Participants must not have certain active infections including HIV or hepatitis
Participants must not be pregnant or breastfeeding
Participants must not have certain types of cancers or certain previous cancer treatments
Participants must not have certain serious medical conditions, including heart or lung disease, or have had certain types of tissue or organ transplants
